stockrowEdwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.
- Revenue
- +10.5%
- EPS
- +6.00%
- Free cash flow
- −1.84%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow EW
Alert me
Edwards Lifesciences Corporation (EW) EBITDA
Edwards Lifesciences Corporation's EBITDA for fiscal 2025 was $1.4B, down 7.37% from $1.5B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.6B. Over the past ten years it has ranged from $708.5M (fiscal 2015) to $1.8B (fiscal 2021); the current reading is higher than 64% of that period. Edwards Lifesciences Corporation ranks 10th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.4B | (7.37%) |
| FY2024 | $1.5B | 5.51% |
| FY2023 | $1.5B | (11.25%) |
| FY2022 | $1.6B | (10.25%) |
| FY2021 | $1.8B | 81.64% |
| FY2020 | $1.0B | (18.71%) |
| FY2019 | $1.2B | 49.72% |
| FY2018 | $825.6M | (29.51%) |
| FY2017 | $1.2B | 36.99% |
| FY2016 | $855.0M | 20.68% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $344.0M | (38.12%) |
| Jun 2026 | $555.9M | 7.21% |
| Mar 2026 | $518.5M | 167.54% |
| Dec 2025 | $193.8M | (44.04%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MDT Medtronic PLC compare | $9.7B |
| SYK Stryker Corporation compare | $6.6B |
| BSX Boston Scientific Corporation compare | $5.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.5B |
| PHG Koninklijke Philips N.V. compare | $3.1B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $2.3B |
| STE STERIS plc compare | $1.7B |
| EW Edwards Lifesciences Corporation | $1.6B |
| DXCM DexCom, Inc. compare | $1.5B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on EW
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement